

Huimin Geng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11908290/publications.pdf>

Version: 2024-02-01

149
papers

5,016
citations

94381

37
h-index

98753

67
g-index

157
all docs

157
docs citations

157
times ranked

8842
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2010, 115, 1026-1036.	0.6	353
2	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. <i>Blood</i> , 2010, 116, 5247-5255.	0.6	262
3	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017, 7, 38-53.	7.7	218
4	Metabolic gatekeeper function of B-lymphoid transcription factors. <i>Nature</i> , 2017, 542, 479-483.	13.7	175
5	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. <i>Nature</i> , 2011, 473, 384-388.	13.7	174
6	TET1 is a tumor suppressor of hematopoietic malignancy. <i>Nature Immunology</i> , 2015, 16, 653-662.	7.0	173
7	Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. <i>Nature Immunology</i> , 2015, 16, 766-774.	7.0	163
8	Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. <i>Blood Advances</i> , 2018, 2, 1595-1607.	2.5	143
9	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, e81-e89.	0.6	138
10	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3351-3362.	3.9	133
11	RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction. <i>Cell Reports</i> , 2013, 3, 116-127.	2.9	130
12	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015, 521, 357-361.	13.7	127
13	Polyphenol-Based Particles for Theranostics. <i>Theranostics</i> , 2019, 9, 3170-3190.	4.6	123
14	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , 2015, 13, 2715-2727.	2.9	118
15	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	7.7	109
16	Metal Ion-Directed Functional Metal-Phenolic Materials. <i>Chemical Reviews</i> , 2022, 122, 11432-11473.	23.0	108
17	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 114-128.	7.7	107
18	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137.	1.5	102

#	ARTICLE	IF	CITATIONS
19	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. <i>Blood</i> , 2013, 121, 1814-1818.	0.6	102
20	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , 2013, 19, 1014-1022.	15.2	100
21	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. <i>Nature Medicine</i> , 2016, 22, 379-387.	15.2	94
22	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. <i>Cell</i> , 2018, 173, 470-484.e18.	13.5	89
23	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. <i>Blood</i> , 2014, 123, 1699-1708.	0.6	83
24	Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. <i>BMC Genomics</i> , 2007, 8, 230.	1.2	82
25	Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2012, 2, 1004-1023.	7.7	80
26	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2219-28.	3.3	78
27	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2127.	5.8	75
28	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. <i>Nature Immunology</i> , 2019, 20, 86-96.	7.0	71
29	MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. <i>Cell Reports</i> , 2017, 18, 482-495.	2.9	69
30	Injectable and Sprayable Polyphenol-Based Hydrogels for Controlling Hemostasis. <i>ACS Applied Bio Materials</i> , 2020, 3, 1258-1266.	2.3	66
31	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 148-155.	0.6	61
32	Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. <i>Blood</i> , 2011, 118, 4174-4178.	0.6	58
33	BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis. <i>Nature Genetics</i> , 2020, 52, 1384-1396.	9.4	57
34	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. <i>Nature</i> , 2020, 588, 491-497.	13.7	57
35	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. <i>Blood</i> , 2018, 132, 2026-2039.	0.6	48
36	Low-Molecular-Weight Organo- and Hydrogelators Based on Cyclo(Lys-Glu). <i>Langmuir</i> , 2016, 32, 4586-4594.	1.6	44

#	ARTICLE	IF	CITATIONS
37	Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2836-2841.	3.3	44
38	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. <i>Cancer Discovery</i> , 2017, 7, 506-521.	7.7	43
39	Principles of Cation- π Interactions for Engineering Mussel-Inspired Functional Materials. <i>Accounts of Chemical Research</i> , 2022, 55, 1171-1182.	7.6	42
40	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015, 6, 6471.	5.8	41
41	Signalling input from divergent pathways subverts B cell transformation. <i>Nature</i> , 2020, 583, 845-851.	13.7	37
42	Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i> -Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i> -Rearranged B-ALL. <i>Cancer Discovery</i> , 2021, 11, 2032-2049.	7.7	37
43	H3K79me _{2/3} controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. <i>Leukemia</i> , 2021, 35, 90-106.	3.3	35
44	Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL. <i>Journal of Experimental Medicine</i> , 2017, 214, 793-814.	4.2	34
45	E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia. <i>Blood</i> , 2020, 136, 11-23.	0.6	33
46	Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 180-183.	1.2	31
47	Integrin $\alpha 6$ mediates the drug resistance of acute lymphoblastic B-cell leukemia. <i>Blood</i> , 2020, 136, 210-223.	0.6	31
48	A TAF4 coactivator function for E proteins that involves enhanced TFIID binding. <i>Genes and Development</i> , 2013, 27, 1596-1609.	2.7	30
49	CAMKs support development of acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 30.	6.9	26
50	MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 ^{Ac} acetylation. <i>Experimental Hematology</i> , 2017, 47, 64-75.	0.2	25
51	DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. <i>Leukemia</i> , 2020, 34, 938-941.	3.3	24
52	Hot Melt Super Glue: Multi-Recyclable Polyphenol-Based Supramolecular Adhesives. <i>Macromolecular Rapid Communications</i> , 2022, 43, e2100830.	2.0	19
53	Interfacial Assembly of Metal-Phenolic Networks for Hair Dyeing. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 29826-29834.	4.0	18
54	Ultrasound-induced gelation of fluorenyl-9-methoxycarbonyl-L-lysine (fluorenyl-9-methoxycarbonyl)-OH and its dipeptide derivatives showing very low minimum gelation concentrations. <i>Journal of Colloid and Interface Science</i> , 2017, 490, 665-676.	5.0	17

#	ARTICLE	IF	CITATIONS
55	Rationale for targeting BCL6 in <i>t(12;21)</i> -rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , 2019, 33, 1265-1279.	2.7	17
56	Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. <i>Blood</i> , 2012, 120, 528-528.	0.6	17
57	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. <i>Nature Communications</i> , 2021, 12, 5337.	5.8	14
58	Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes. <i>Blood</i> , 2011, 118, 3725-3725.	0.6	11
59	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	10
60	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures. <i>Blood</i> , 2009, 114, 619-619.	0.6	10
61	Convergent architecting of multifunction-in-one hydrogels as wound dressings for surgical anti-infections. <i>Materials Today Chemistry</i> , 2022, 25, 100968.	1.7	10
62	Synthesis and gelation capability of mono- and disubstituted cyclo(L-Glu-L-Glu) derivatives with tyramine, tyrosine and phenylalanine. <i>Colloid and Polymer Science</i> , 2017, 295, 1549-1561.	1.0	9
63	Tumor metabolism and neurocognition in CNS lymphoma. <i>Neuro-Oncology</i> , 2021, 23, 1668-1679.	0.6	9
64	Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12167.	1.8	9
65	A New Clustering Algorithm Using Message Passing and its Applications in Analyzing Microarray Data. <i>Journal of Bioinformatics</i> , 2010, 2010, 1-10.		8
66	In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies. <i>Blood</i> , 2019, 134, 1337-1337.	0.6	8
67	Message Passing Clustering (MPC): a knowledge-based framework for clustering under biological constraints. <i>International Journal of Data Mining and Bioinformatics</i> , 2008, 2, 95.	0.1	7
68	Gelation capability of cysteine-modified cyclo(L-Lys-L-Lys)s dominated by Fmoc and Trt protecting groups. <i>Science China Chemistry</i> , 2016, 59, 293-302.	4.2	7
69	Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature. <i>Experimental Hematology</i> , 2020, 90, 65-71.e1.	0.2	7
70	The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias. <i>Genes and Immunity</i> , 2020, 21, 119-130.	2.2	7
71	Virtual CGH: an integrative approach to predict genetic abnormalities from gene expression microarray data applied in lymphoma. <i>BMC Medical Genomics</i> , 2011, 4, 32.	0.7	6
72	Synthesis and gelation capability of Fmoc and Boc mono-substituted cyclo(L-Lys-L-Lys)s. <i>Chemical Research in Chinese Universities</i> , 2016, 32, 484-492.	1.3	6

#	ARTICLE	IF	CITATIONS
73	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1434-1434.	0.6	6
74	A Study on Synthesis and Gelation Capability of Fmoc and Boc Disubstituted Cyclo(L-Lys-L-Lys)s. <i>Acta Chimica Sinica</i> , 2015, 73, 423.	0.5	6
75	Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL. <i>Blood</i> , 2013, 122, 2505-2505.	0.6	5
76	Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 852-852.	0.6	5
77	ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. <i>Blood</i> , 2012, 120, 291-291.	0.6	5
78	Cross-platform analysis of cancer biomarkers: a Bayesian network approach to incorporating mass spectrometry and microarray data. <i>Cancer Informatics</i> , 2007, 3, 183-202.	0.9	5
79	Learning yeast gene functions from heterogeneous sources of data using hybrid weighted Bayesian networks. , 2005, , 25-34.		4
80	Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3900-3900.	0.6	4
81	Molecular Signatures to Improve Diagnosis, Prognostication and Identification of Oncogenic Pathways in Peripheral T and NK Cell Lymphoma.. <i>Blood</i> , 2008, 112, 3339-3339.	0.6	4
82	On Clustering Biological Data Using Unsupervised and Semi-Supervised Message Passing. , 0, , .		3
83	Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 547-547.	0.6	3
84	A new approach to clustering biological data using message passing. , 0, , .		2
85	IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells. <i>Blood</i> , 2015, 126, 1325-1325.	0.6	2
86	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. <i>Blood</i> , 2016, 128, 4088-4088.	0.6	2
87	Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma. <i>Blood</i> , 2016, 128, 777-777.	0.6	2
88	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis.. <i>Blood</i> , 2009, 114, 3465-3465.	0.6	2
89	BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1301-1301.	0.6	2
90	Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 519-519.	0.6	2

#	ARTICLE	IF	CITATIONS
91	IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation. <i>Blood</i> , 2018, 132, 552-552.	0.6	2
92	BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells. <i>Blood</i> , 2021, 138, 359-359.	0.6	2
93	Polymorphic transient glycolipid assemblies with tunable lifespan and cargo release. <i>Journal of Colloid and Interface Science</i> , 2022, 610, 1067-1076.	5.0	2
94	Mining Gene Microarray Data with Adaptive Feature Scaling. , 0, , .		1
95	A Computational Method to Predict DNA Copy Number Alterations from Gene Expression Data in Tumor Cases. , 2009, , .		1
96	Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph+ leukemia. <i>Experimental Hematology and Oncology</i> , 2015, 5, 5.	2.0	1
97	Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma. <i>Blood</i> , 2018, 132, 4230-4230.	0.6	1
98	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. <i>Blood</i> , 2011, 118, 1479-1479.	0.6	1
99	Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL. <i>Blood</i> , 2012, 120, 872-872.	0.6	1
100	Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells. <i>Blood</i> , 2013, 122, 2506-2506.	0.6	1
101	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013, 122, 3736-3736.	0.6	1
102	Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. <i>Blood</i> , 2012, 120, 1352-1352.	0.6	1
103	Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 349-349.	0.6	1
104	Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism. <i>Blood</i> , 2016, 128, 4069-4069.	0.6	1
105	PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 1056-1056.	0.6	1
106	Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis. <i>Blood</i> , 2019, 134, 2782-2782.	0.6	1
107	Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions. <i>Blood</i> , 2019, 134, 746-746.	0.6	1
108	Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 616-616.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Survival and Patient-Reported Outcomes of Older Adults with Primary Central Nervous System Lymphoma on Low-Dose Lenalidomide. <i>Blood</i> , 2020, 136, 21-22.	0.6	1
110	Virtual CGH: Prediction of Novel Regions of Chromosomal Alterations in Tumor from Gene Expression Profiling. , 2007, , .		0
111	Analysis of Gene Expression Patterns and Gene Copy Number Changes in Human NK Cell Malignancies.. <i>Blood</i> , 2006, 108, 2228-2228.	0.6	0
112	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. <i>Blood</i> , 2008, 112, 2049-2049.	0.6	0
113	Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias. <i>Blood</i> , 2011, 118, 1382-1382.	0.6	0
114	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. <i>Blood</i> , 2011, 118, 1406-1406.	0.6	0
115	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 562-562.	0.6	0
116	SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 863-863.	0.6	0
117	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. <i>Blood</i> , 2012, 120, 1300-1300.	0.6	0
118	Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.. <i>Blood</i> , 2012, 120, 2563-2563.	0.6	0
119	Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis. <i>Blood</i> , 2012, 120, 34-34.	0.6	0
120	Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2012, 120, 2565-2565.	0.6	0
121	Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL. <i>Blood</i> , 2012, 120, 874-874.	0.6	0
122	Global Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes In Natural Killer Cell Lymphomas. <i>Blood</i> , 2013, 122, 1262-1262.	0.6	0
123	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. <i>Blood</i> , 2013, 122, 229-229.	0.6	0
124	Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1250-1250.	0.6	0
125	The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL. <i>Blood</i> , 2013, 122, 836-836.	0.6	0
126	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. <i>Blood</i> , 2013, 122, 72-72.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3716-3716.	0.6	0
128	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. Blood, 2015, 126, 556-556.	0.6	0
129	PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 902-902.	0.6	0
130	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	0.6	0
131	Identification of IRF8 As a Potent Tumor Suppressor in Murine Acute Promyelocytic Leukemia. Blood, 2016, 128, 1518-1518.	0.6	0
132	Genetic Subtypes of Human Pediatric ALLs Show Gene Expression Differences That Parallel Those Observed in Mouse B1 and B2 Progenitors, Suggesting Divergent Developmental Origins. Blood, 2016, 128, 1741-1741.	0.6	0
133	IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies. Blood, 2016, 128, 2738-2738.	0.6	0
134	Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2771-2771.	0.6	0
135	Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation. Blood, 2016, 128, 437-437.	0.6	0
136	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. Blood, 2016, 128, 438-438.	0.6	0
137	Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. Blood, 2018, 132, 568-568.	0.6	0
138	Application of Hyperpolarized ¹³ C Magnetic Resonance Imaging to Detect Target Inhibition of NFκB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. Blood, 2018, 132, 2840-2840.	0.6	0
139	CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies. Blood, 2018, 132, 776-776.	0.6	0
140	Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling. Blood, 2018, 132, 1336-1336.	0.6	0
141	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. Blood, 2019, 134, 393-393.	0.6	0
142	Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL. Blood, 2019, 134, 3785-3785.	0.6	0
143	Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation. Blood, 2019, 134, 3944-3944.	0.6	0
144	Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies. Blood, 2019, 134, 1494-1494.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. Blood, 2019, 134, 1239-1239.	0.6	0
146	Lgr5 Functions As a Critical Negative Regulator of Wnt/ β 2-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation. Blood, 2019, 134, 748-748.	0.6	0
147	Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation. Blood, 2021, 138, 792-792.	0.6	0
148	Functional Multi-Omics Reveals Genetic and Pharmacologic Regulation of Surface CD38 in Multiple Myeloma. Blood, 2021, 138, 2648-2648.	0.6	0
149	Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies. Blood, 2021, 138, 355-355.	0.6	0